7:50 am Morning Coffee
8:50 am Chair’s Opening Remarks
Spotlighting the Latest Clinical Updates & Where to Go Next for Sustainable Commercialization of Bacteriophages
9:00 am Executing Definitive Pivotal Trials for Bacteriophages to Prove Clinical Efficacy
Synopsis
- Spearheading randomized clinical trials of bacteriophages to meet regulatory standards
- How to move beyond compassionate use of bacteriophages to obtain robust clinical evidence
- Navigating the ethical considerations in placebo-controlled trials to demonstrate bacteriophage superiority over antibiotics
New Data!
9:30 am Fireside Chat: How Can Bacteriophage Therapies be Sustainable in the Market?
Synopsis
- What indications should be prioritized to bring the first phage therapies to market
- How to ensure companies will sell bacteriophage therapy after receiving approval
- Understanding that route for smaller businesses who are working in the bacteriophage space
10:30 am Morning Networking Break
Supercharging the Global Distribution of Stable Bacteriophages with Effective Business Models to Deliver Therapy to Patient in Need
11:15 am Roundtable Discussion: Rethinking the Business Model for Bacteriophages to Develop Effective Therapies to Take to Market
Synopsis
- How to identify investors and initiatives to give financial support
- Communicating the advantage of bacteriophages to funders as valid alternatives to antibiotics
- How to adapt business models for non-traditional bacteriophage therapies to be economically viable
12:00 pm Developing an Off-the-shelf Bacteriophage Cocktail Invention for Cholera in Low- & Middle-Income Countries
Synopsis
- Targeting bacteria that cause cholera with bacteriophage cocktails for high coverage against strains
- Manufacturing encapsulated and spray-dried bacteriophages to remain stable in hot climates with no refrigeration
- Globally distributing and monitoring bacteriophage therapies
New Data!
12:30 pm Networking Lunch
Developing Personalized & Off-the-shelf Bacteriophage Therapies for a Wide Range of Indications
1:30 pm Exploring Personalized vs Off-the-shelf Phage Therapies as Most Effective Therapies to Achieve Market Approval
Synopsis
- Utilizing personalized phage therapies that are tailored for specific disease indications
- How to choose an individualized or off-the-shelf phage therapy based on disease indication
- Developing a broad range phage cocktail as a rapid response to infection
New Company!
2:00 pm Investigating Jumbo Bacteriophages as Personalized & Off-the-shelf Therapies to Difficult-to-Treat Infections
Synopsis
- How to choose an individualized or off-the-shelf phage therapy based on disease indication
- Creating a biobank to develop population-centric bacteriophage therapies
- Exploring inhalation, topical, and intravenous application of bacteriophages to treat a range of infectious diseases
New Company!
New Data!
2:30 pm Afternoon Break
3:15 pm Engineered Phage Tail-Like Bacteriocins as Human Therapeutics
Synopsis
- Phage tail-like bacteriocins can be retargeted by engineering receptor binding proteins
- These structures have in vivo bactericidal activity and can be used for treatment of infectious disease or microbiome manipulation
- Methodologies can be interchanged with phages
New Company!
3:45 pm Developing Engineered Lysin Proteins to Combat Antibiotic-Resistant Bacteria
Synopsis
- Using DNA shuffling technology for recombinant assembly of high dimensional libraries of engineered lysins
- Integrating high-throughput production and screening of lysins active against gramnegative bacteria
- Maintaing activity of lysins under physiological conditions
New Company!